Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2024-08-26 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司2024 年半年度报告全文" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2024 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, business overview, R&D updates, financial metrics, and other comprehensive information typical of a semi-annual or interim financial report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. The presence of financial statements, management analysis, and detailed operational data confirms it is a substantive financial report for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-26 Chinese
关于JK06境外临床试验进展的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Salubris Biotherapeutics regarding the progress of a clinical trial for a drug named JK06. It provides details about the clinical trial approval and the drug's characteristics but does not contain financial data, regulatory certifications, or detailed financial reports. The document is relatively short (940 characters) and serves as a progress update on a clinical trial, which is a regulatory announcement related to company operations but not a financial report or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress that does not fit other specific categories.
2024-08-05 Chinese
关于恩那度司他新适应症获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval of a clinical trial for a new indication of their drug Ennadustat. It is a regulatory announcement about receiving a clinical trial approval notice from the National Medical Products Administration. The document does not contain financial data, earnings, or detailed reports but is a formal disclosure of a regulatory milestone related to drug development. It is not an annual report, earnings release, or management discussion. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit other specific categories.
2024-07-31 Chinese
关于SAL0120获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the receipt of a clinical trial approval notice for their drug SAL0120. It contains no financial data, no management discussion, no voting results, no regulatory certifications, or other report content. The document is short (1192 characters) and serves as an official announcement of a regulatory approval event related to clinical trials. It does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is not a management or board change announcement, nor a legal proceeding or capital update. The content is a regulatory announcement about clinical trial approval, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2024-07-30 Chinese
关于第三期员工持股计划完成非交易过户暨回购股份处理完成的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the completion of non-trade transfer of shares under the company's third employee stock ownership plan and the completion of share repurchase processing. It details the background of the share repurchase, the source and quantity of shares, subscription and transfer details, related party relationships, and accounting treatment. The document is a formal announcement of corporate actions related to employee stock plans and share repurchases, not a financial report, earnings release, or management discussion. It is not a full report but an announcement of completed corporate actions. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers company buyback or issuance of its own shares.
2024-07-11 Chinese
关于苯甲酸福格列汀片（信立汀）获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the receipt of a drug registration certificate for a new pharmaceutical product. It includes details about the drug, regulatory approval, and potential impact on the company. The document is short (1099 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not a report publication announcement since it does not mention the release of a report but rather announces a regulatory milestone. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-07-05 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.